Integrating New Agents to Optimize Multiple Myeloma Care: Expert Answers to Frequently Asked Questions
Source: Integrating New Agents to Optimize Multiple Myeloma Care: Expert Guidance for the Practicing Clinician

Module

Expert answers to frequently asked questions about new agents for the treatment of multiple myeloma, including recently approved therapies and those on the horizon with the potential to change clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the newly approved monoclonal antibodies daratumumab and elotuzumab into existing treatment strategies for patients with myeloma
  • Plan appropriate treatment strategies using the new-generation proteasome inhibitors carfilzomib and ixazomib for individual patients with myeloma
  • Apply data recently presented at major hematology/medical oncology meetings to clinical practice
  • Develop a proactive management plan for adverse events associated with new agents used to treat myeloma

Topics covered include:

  • Diagnosis
  • Imaging
  • Transplantation
  • Supportive Care
  • Future Directions
 

Program Directors

  • Melissa Alsina
    MD
    Suzanne Lentzsch
    MD, PhD

Faculty

  • Ajai Chari
    MD
    Raymond L. Comenzo
    MD
    Jonathan L. Kaufman
    MD
    Amrita Krishnan
    MD, FACP
    Elisabet E. Manasanch
    MD
  • Release Date:
    March 09, 2018

Information on this Educational Activity

Program Directors

Melissa Alsina, MD

Head, Multiple Myeloma BMT Program
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Melissa Alsina, MD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Amgen and Janssen, and funds for research support from Amgen.

 

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD, has disclosed that she has received consulting fees from Amgen, Bristol-Myers Squibb, and Caelum Biosciences and has ownership interest in Caelum Biosciences.

 

Faculty

Ajai Chari, MD


Associate Professor of Medicine
Mount Sinai School of Medicine
Director of Clinical Research
Multiple Myeloma Program
New York, New York

Ajai Chari, MD, has disclosed that he has received consulting fees from Amgen, Celgene, Janssen, and Takeda.
 

Raymond L. Comenzo, MD


Director, John Conant Davis Myeloma and Amyloid Program
Tufts Medical Center
Professor of Medicine and Pathology
Tufts University School of Medicine
Boston, Massachusetts

Raymond L. Comenzo, MD, has disclosed that he has received consulting fees from Janssen and Prothena.
 

Jonathan L. Kaufman, MD


Associate Professor
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jonathan L. Kaufman, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Roche, Seattle Genetics, and Sutro and has served on the data and safety monitoring committee for Incyte, Pharmacyclics, and TG Therapeutics.
 

Amrita Krishnan, MD, FACP


Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
City of Hope
Duarte, California

Amrita Krishnan, MD, FACP, has disclosed that she has received consulting fees from Adaptive Biotechnologies, Celgene, Janssen, and Kite Pharma; has received fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Celgene, Janssen, Onyx, and Takeda; and has ownership interest in Celgene.
 

Elisabet E. Manasanch, MD


Assistant Professor
Division of Cancer Medicine
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabet E. Manasanch, MD, has disclosed that she has received consulting fees from Amgen and Takeda and funds for research support from Merck, Quest, and Sanofi-Aventis.
 

Staff

Kristen M. Rosenthal, PhD


Senior Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

Terrence Fagan, 


Associate Managing Editor

Terrence Fagan has no real or apparent conflicts of interest to report.